Results 201 to 210 of about 39,319 (333)

ECONOMIC EVALUATION OF IBRUTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA IN MEXICO [PDF]

open access: bronze, 2016
F. Carlos   +4 more
openalex   +1 more source

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]

open access: yesCancer Immunol Immunother
Bopp AR   +10 more
europepmc   +1 more source

Ibrutinib

open access: yesReactions Weekly, 2021
openaire   +1 more source

Modelling the Effectiveness of Ibrutinib Versus Rituximab-Based Chemotherapy Regimens in Relapsed/Refractory Mantle Cell Lymphoma [PDF]

open access: bronze, 2016
Simone Critchlow   +6 more
openalex   +1 more source

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia

open access: gold, 2015
Martin F. M. de Rooij   +6 more
openalex   +1 more source

IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL [PDF]

open access: bronze, 2017
Paula Cramer   +19 more
openalex   +1 more source

Ibrutinib therapy for lymphoplasmacytic lymphoma [PDF]

open access: yesAmerican Journal of Hematology, 2017
Margaret J. Helber   +5 more
openaire   +3 more sources

Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting. [PDF]

open access: yesCurr Oncol
Othman I   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy